The McGill Clinical Genomics program (McG) aims to implement hospital-based genomic medicine building on robust research to improve clinical care. McG seeks to improve disease diagnosis and risk-stratification, the efficiency of test ordering and prediction of drug responses that will deliver benefits to person-centered patient care and value to the wider healthcare system and across the CIUSSS du Centre-Ouest-de-l’Île-de-Montréal/Center West Montreal.
The McGill Clinical Genomics Biobank will undertake genetic studies and other health research studies. All of this data will be identified by a code and remain confidential. We intend to share this data with qualified researchers in academia and industry, after approval, to support studies that help to improve understanding of risk factors, causes of diseases, prediction of drug responses and improvement of clinical care in COVID-19 infection.
Hôpital général juif/Jewish General Hospital
Biobanque COVID19 BioBank
Avez-vous testé positif à la COVID19? Si oui, seriez-vous intéressé de contribute à la recherche sur la COVID19? Pour obtenir plus d'informations, prenez rendez-vous avec un de nos coordonnateurs de recherche.
Vous receverez un honoraire de 50 $ pour compenser votre transport. Vous avez aussi l’option d’obtenir un test d’anticorps pour la COVID19 au lieu de l’honoraire de 50 $.
Hôpital général juif/Jewish General Hospital
Biobanque COVID19 BioBank
Have you tested positive for COVID19? If yes, would you be interested in contributing to COVID19 research? To get more information, please book an appointment with one of our research coordinators.
You will receive a $50 transportation honorarium or a COVID19 antibody test in lieu of the $50 honorarium if you choose.
For the latest information on McGill's response to COVID-19, please visit the Coronavirus Information website.
For Researchers
Biobanque Québec COVID-19 Data Release 4
The JGH Site of the Biobanque Québec COVID-19 (bqc19.ca) has collected samples and/or data from over 1710 individuals. The following data from BQC19 JGH site participants will be released in the fourth data release for use by approved investigators:
Clinical variables on available individuals: ~1,710
Genome-wide genotyping data on available individuals: ~1,290
Whole genome sequence data on available individuals: ~1,106
Proteomics data on available individuals: ~1,241
Metabolon metabolomics data on available individuals: ~1,265
Viral sequencing data on available individuals: ~417
This data release process will be managed by The McGill Interdisciplinary Initiative in Infection and Immunity (MI4) and is being released rapidly to enable COVID-19 research.
Applications for access to data are encouraged from investigators at academic institutions, within industry and from all countries.
Interested parties should fill out the Access Form and send to bcq19imi4.med [at] mcgill.ca (bcq19imi4[dot]med[at]mcgill[dot]ca)
Biobanque Québec COVID-19 JGH Site Third Samples Release
We are pleased to announce the availability of biological samples from the Jewish General Hospital site of the Biobanque Québec COVID19 (BQC19) for use by researchers at academic institutions, within industry and from all countries. The JGH site has collected PBMC samples from 1132 individuals at different time points (for a total of 1863 samples) and Plasma samples from 1646 individuals at different time points (for a total of 3157 samples) who were tested with SARS-CoV-2 nasal swabs at the JGH.
The JGH has elected to share these samples with researchers through the MI4 program, which will use an independent, external peer review committee to decide how to use these samples.
Please send your completed application to the following email address: bcq19imi4.med [at] mcgill.ca (bcq19imi4[dot]med[at]mcgill[dot]ca)
